Dinutuxumab Beta Plus Conventional Chemotherapy for Relapsed/Refractory High-Risk Neuroblastoma: A Single Centre Experience

被引：0
|
作者：
Olgun, N. [1 ]
Cecen, R. E. [1 ]
Ince, D. [1 ]
Onal, A. [1 ]
Baysal, B. [2 ]
Akyol, S. [1 ]
Ozdogan, O. [3 ]
Guleryuz, H. [4 ]
Aktas, S. [1 ]
Ozer, E. [5 ]
机构：
[1] Dokuz Eylul Univ, Inst Oncol, Izmir, Turkey
[2] Marmara Univ, Educ & Res Hosp, Pediat Hematol & Oncol, Istanbul, Turkey
[3] Dokuz Eylul Univ, Nucl Med, Izmir, Turkey
[4] Dokuz Eylul Univ, Radiodiagnost, Izmir, Turkey
[5] Dokuz Eylul Univ, Pathol, Izmir, Turkey
来源：
PEDIATRIC BLOOD & CANCER | 2021年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PV0129
引用
收藏
页码：S215 / S215
页数：1
相关论文
共 50 条
  • [1] Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
    Olgun, Nur
    Cecen, Emre
    Ince, Dilek
    Kizmazoglu, Deniz
    Baysal, Birsen
    Onal, Ayse
    Ozdogan, Ozhan
    Guleryuz, Handan
    Cetingoz, Riza
    Demiral, Ayse
    Olguner, Mustafa
    Celik, Ahmet
    Kamer, Serra
    Ozer, Erdener
    Altun, Zekiye
    Aktas, Safiye
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] EVALUATION OF ADVERSE EVENTS IN PATIENTS WITH RELAPSED REFRACTORY NEUROBLASTOMA RECEIVING DINUTUXIMAB BETA PLUS CONVENTIONAL CHEMOTHERAPY
    Kizmazoglu, Deniz
    Cecen, Emre
    Ince, Dilek
    Laleoglu, Pelin
    Onal, Ayse
    Olgun, Nur
    PEDIATRIC BLOOD & CANCER, 2023, 70
  • [3] Prognosis of Patients with Relapsed, High-risk Neuroblastoma: A Single Center Experience
    Yamada, Yuji
    Kiyotani, Chikako
    Shioda, Yoko
    Osumi, Tomoo
    Kato, Motohiro
    Tomizawa, Daisuke
    Terashima, Keita
    Hishiki, Tomoro
    Fujino, Akihiro
    Kanamori, Yutaka
    Fuji, Hiroshi
    Yoshioka, Takako
    Miyazaki, Osamu
    Matsumoto, Kimikazu
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S41 - S42
  • [4] Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
    Tran, Hung C.
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima F.
    Mascarenhas, Leo
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2015, 32 (01) : 26 - 31
  • [5] OXALIPLATIN AND DOXORUBICIN TREATMENT FOR RELAPSED AND REFRACTORY HIGH-RISK NEUROBLASTOMA
    Hung Tran
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima
    Mascarenhas, Leo
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S73 - S73
  • [6] Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
    Koelker-Wolfe, E. R.
    Marcus, K. J.
    Dubois, S. G.
    Shusterman, S.
    Ioakeim-Ioannidou, M.
    Yock, T. I.
    MacDonald, S.
    Haas-Kogan, D. A.
    Liu, K. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E487 - E488
  • [7] Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
    Koelker-Wolfe, Ellery
    Marcus, Karen J.
    Dubois, Steven G.
    Catalano, Paul J.
    Shusterman, Suzanne
    Ioakeim-Ioannidou, Myrsini
    Elhalawani, Hesham
    Yock, Torunn I.
    Macdonald, Shannon M.
    Haas-Kogan, Daphne A.
    Liu, Kevin X.
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [8] Intraoperative Radiation Therapy for Relapsed or Refractory High-Risk Neuroblastoma: A 27-Year Experience
    Conte, Brianna
    Casey, Dana L.
    Tringale, Kathryn R.
    Honeyman, Joshua
    Narayan, Nicole J. C.
    Laquaglia, Michael P.
    Gerstle, Justin Ted
    Modak, Shakeel
    Kushner, Brian H.
    Kramer, Kim
    Wolden, Suzanne L.
    PRACTICAL RADIATION ONCOLOGY, 2024, 14 (03) : e226 - e232
  • [9] Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
    Wieczorek, Aleksandra
    Zaniewska-Tekieli, Anna
    Ehlert, Karoline
    Pawinska-Wasikowska, Katarzyna
    Balwierz, Walentyna
    Lode, Holger
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
    Quintarelli, Concetta
    del Bufalo, Francesca
    Locatelli, Franco
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2303 - 2304
12345